351 related articles for article (PubMed ID: 21132183)
1. Synthesis, structure and biological evaluation of bis salicylaldehyde-4(N)-ethylthiosemicarbazone ruthenium(iii) triphenylphosphine.
Prabhakaran R; Kalaivani P; Jayakumar R; Zeller M; Hunter AD; Renukadevi SV; Ramachandran E; Natarajan K
Metallomics; 2011 Jan; 3(1):42-8. PubMed ID: 21132183
[TBL] [Abstract][Full Text] [Related]
2. Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.
Ludwig G; Kaluđerović GN; Rüffer T; Bette M; Korb M; Block M; Paschke R; Lang H; Steinborn D
Dalton Trans; 2013 Mar; 42(11):3771-4. PubMed ID: 23340605
[TBL] [Abstract][Full Text] [Related]
3. Influence of terminal substitution on structural, DNA, protein binding, anticancer and antibacterial activities of palladium(II) complexes containing 3-methoxy salicylaldehyde-4(N) substituted thiosemicarbazones.
Kalaivani P; Prabhakaran R; Ramachandran E; Dallemer F; Paramaguru G; Renganathan R; Poornima P; Vijaya Padma V; Natarajan K
Dalton Trans; 2012 Feb; 41(8):2486-99. PubMed ID: 22222360
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium(II)/(III) complexes of 4-hydroxy-pyridine-2,6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: impact of oxidation state and co-ligands on anticancer activity in vitro.
Kamatchi TS; Chitrapriya N; Lee H; Fronczek CF; Fronczek FR; Natarajan K
Dalton Trans; 2012 Feb; 41(7):2066-77. PubMed ID: 22183160
[TBL] [Abstract][Full Text] [Related]
5. Vanadium(V) complexes with salicylaldehyde semicarbazone derivatives bearing in vitro anti-tumor activity toward kidney tumor cells (TK-10): crystal structure of [VVO2(5-bromosalicylaldehyde semicarbazone)].
Noblía P; Vieites M; Parajón-Costa BS; Baran EJ; Cerecetto H; Draper P; González M; Piro OE; Castellano EE; Azqueta A; López de Ceráin A; Monge-Vega A; Gambino D
J Inorg Biochem; 2005 Feb; 99(2):443-51. PubMed ID: 15621276
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, X-ray structure, physicochemical properties and anticancer activity of mer and fac Ru(iii) triphenylphosphine complexes with a benzothiazole derivative as a co-ligand.
Richert M; Walczyk M; Cieślak MJ; Kaźmierczak-Barańska J; Królewska-Golińska K; Wrzeszcz G; Muzioł T; Biniak S
Dalton Trans; 2019 Jul; 48(28):10689-10702. PubMed ID: 31241117
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium(III) S-methylisothiosemicarbazone Schiff base complexes bearing PPh3/AsPh3 coligand: synthesis, structure and biological investigations, including antioxidant, DNA and protein interaction, and in vitro anticancer activities.
Prakash G; Manikandan R; Viswanathamurthi P; Velmurugan K; Nandhakumar R
J Photochem Photobiol B; 2014 Sep; 138():63-74. PubMed ID: 24911273
[TBL] [Abstract][Full Text] [Related]
8. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
9. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
10. DNA binding, antioxidant, cytotoxicity (MTT, lactate dehydrogenase, NO), and cellular uptake studies of structurally different nickel(II) thiosemicarbazone complexes: synthesis, spectroscopy, electrochemistry, and X-ray crystallography.
Prabhakaran R; Kalaivani P; Huang R; Poornima P; Vijaya Padma V; Dallemer F; Natarajan K
J Biol Inorg Chem; 2013 Feb; 18(2):233-247. PubMed ID: 23274397
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium(II) carbonyl complexes containing S-methylisothiosemicarbazone based tetradentate ligand: synthesis, characterization and biological applications.
Selvamurugan S; Ramachandran R; Viswanathamurthi P
Biometals; 2013 Oct; 26(5):741-53. PubMed ID: 23780567
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cancer cell growth by ruthenium(II) cyclopentadienyl derivative complexes with heteroaromatic ligands.
Helena Garcia M; Morais TS; Florindo P; Piedade MF; Moreno V; Ciudad C; Noe V
J Inorg Biochem; 2009 Mar; 103(3):354-61. PubMed ID: 19128838
[TBL] [Abstract][Full Text] [Related]
13. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents.
Camm KD; El-Sokkary A; Gott AL; Stockley PG; Belyaeva T; McGowan PC
Dalton Trans; 2009 Dec; (48):10914-25. PubMed ID: 20023922
[TBL] [Abstract][Full Text] [Related]
15. Role of substitution at terminal nitrogen of 2-oxo-1,2-dihydroquinoline-3-carbaldehyde thiosemicarbazones on the coordination behavior and structure and biological properties of their palladium(II) complexes.
Ramachandran E; Senthil Raja D; Rath NP; Natarajan K
Inorg Chem; 2013 Feb; 52(3):1504-14. PubMed ID: 23323516
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium(II/III)-based compounds with encouraging antiproliferative activity against non-small-cell lung cancer.
Nagy EM; Pettenuzzo A; Boscutti G; Marchiò L; Dalla Via L; Fregona D
Chemistry; 2012 Nov; 18(45):14464-72. PubMed ID: 23012112
[TBL] [Abstract][Full Text] [Related]
17. Influence of PPh₃ moiety in the anticancer activity of new organometallic ruthenium complexes.
Sáez R; Lorenzo J; Prieto MJ; Font-Bardia M; Calvet T; Omeñaca N; Vilaseca M; Moreno V
J Inorg Biochem; 2014 Jul; 136():1-12. PubMed ID: 24690555
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, X-ray crystal structure, DNA binding, antioxidant and cytotoxicity studies of Ni(ii) and Pd(ii) thiosemicarbazone complexes.
Ramachandran E; Kalaivani P; Prabhakaran R; Rath NP; Brinda S; Poornima P; Padma VV; Natarajan K
Metallomics; 2012 Feb; 4(2):218-27. PubMed ID: 22101384
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, and anticancer activity of ruthenium-pyrazole complexes.
David S; Perkins RS; Fronczek FR; Kasiri S; Mandal SS; Srivastava RS
J Inorg Biochem; 2012 Jun; 111():33-9. PubMed ID: 22484498
[TBL] [Abstract][Full Text] [Related]
20. From catalysts to bioactive organometallics: do Grubbs catalysts trigger biological effects?
Oehninger L; Alborzinia H; Ludewig S; Baumann K; Wölfl S; Ott I
ChemMedChem; 2011 Dec; 6(12):2142-5. PubMed ID: 21901835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
